Atazanavir – 5 mg

Brand:
Cayman
CAS:
198904-31-3
Storage:
-20
UN-No:
De Minimis - 3077 / 9

Atazanavir is an azapeptide inhibitor of HIV-1 protease (Ki = 2.66 nM).{24185} It has antiviral activity against a variety of HIV-1 strains in several cell types with EC50 values ranging from 2.62 to 5.28 nM. Atazanavir exhibits a minor synergistic effect when used in combination with the reverse transcriptase inhibitor zidovudine (Item No. 15492) in HIV-1-infected human peripheral blood mononuclear cells (PBMCs) and an additive effect when used in combination with several additional reverse transcriptase or HIV-1 protease inhibitors. Atazanavir also inhibits UDP-glucuronyltransferase 1A1 (UGT1A1), which is involved in bilirubin clearance.{24184} Formulations containing atazanavir have been used in combination therapy for the treatment of HIV-1 infection.  

 

Available on backorder

SKU: 11733 - 5 mg Category:

Description

An azapeptide inhibitor of HIV-1 protease (Ki = 2.66 nM). It has antiviral activity against a variety of HIV-1 strains in several cell types (EC50 = 2.62-5.28 nM); exhibits a minor synergistic effect when used in combination with zidovudine in HIV-1-infected human PBMCs and an additive effect when used in combination with several additional reverse transcriptase or HIV-1 protease inhibitors; inhibits UGT1A1, which is involved in bilirubin clearance


Formal name: 3S,12S-bis(1,1-dimethylethyl)-8S-hydroxy-4,11-dioxo-9S-(phenylmethyl)-6-[[4-(2-pyridinyl)phenyl]methyl]-2,5,6,10,13-pentaazatetradecanedioic acid, 1,14-dimethyl ester

Synonyms:  BMS 232632|CGP 73547

Molecular weight: 704.9

CAS: 198904-31-3

Purity: ≥95%

Formulation: A crystalline solid


Product Type|Biochemicals|Antivirals|Protease Inhibitors||Product Type|Biochemicals|Small Molecule Inhibitors|Peptidases & Proteases||Research Area|Immunology & Inflammation||Research Area|Infectious Disease|Viral Diseases|HIV & AIDS